GKB Ophthalmics

₹93 1.1 | 1.2%

WEBSITE BSE:533212 NSE : GKB OPHTHA 15 Jan, 14:01

Market Cap ₹47 Cr.

Stock P/E -15.5

P/B 0.8

Current Price ₹93

Book Value ₹ 115.4

Face Value 10

52W High ₹136.4

Dividend Yield 0%

52W Low ₹ 74.1

Edit Ratio

GKB Ophthalmics Research see more...

Overview Inc. Year: 1981Industry: Medical Equipment/Supplies/Accessories

GKB Ophthalmics Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

GKB Ophthalmics Quarterly Results

#(Fig in Cr.)	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Net Sales	18	19	19	20	22	20	24	22	26	26
Other Income	0	0	-0	0	0	0	0	0	0	0
Total Income	18	19	19	20	23	21	24	22	26	26
Total Expenditure	15	17	19	20	21	21	25	22	25	26
Operating Profit	3	2	-0	-0	2	0	-0	1	1	0
Interest	0	0	0	0	0	0	0	1	1	1
Depreciation	0	0	0	2	1	1	1	1	1	1
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	2	1	-1	-2	1	-1	-1	-1	0	-1
Provision for Tax	-0	-0	0	-0	0	0	0	0	0	0
Profit After Tax	2	1	-1	-2	1	-1	-1	-1	-0	-1
Adjustments	-0	-0	0	0	-0	0	0	0	-0	-0
Profit After Adjustments	2	1	-1	-2	1	-1	-1	-1	-0	-1
Adjusted Earnings Per Share	3.8	1.7	-2.1	-3.8	1	-2.3	-2.5	-1.8	-0.5	-2.4

GKB Ophthalmics Profit & Loss

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Net Sales	41	35	44	74	77	57	59	57	71	75	88	98
Other Income	1	1	2	1	0	2	0	2	1	1	2	0
Total Income	42	36	46	75	78	59	59	59	72	76	90	98
Total Expenditure	34	34	46	72	76	56	56	55	66	72	88	98
Operating Profit	8	1	0	3	2	3	3	4	6	5	2	2
Interest	3	2	2	1	1	1	1	2	1	2	2	3
Depreciation	1	2	1	1	2	4	4	3	3	3	3	4
Exceptional Income / Expenses	0	1	11	3	0	0	0	-1	0	0	0	0
Profit Before Tax	5	-2	8	3	-1	-2	-2	-1	2	0	-3	-3
Provision for Tax	2	-1	4	0	-0	-0	0	-0	0	0	0	0
Profit After Tax	2	-1	4	3	-1	-1	-2	-1	2	0	-3	-3
Adjustments	2	1	0	0	0	0	1	-0	-1	-0	0	0
Profit After Adjustments	4	0	4	3	-1	-1	-2	-1	1	-0	-3	-3
Adjusted Earnings Per Share	9.6	0	9.5	6.2	-2.3	-2.4	-3.6	-1.8	2.5	-0.3	-5.6	-7.2

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	17%	16%	9%	8%
Operating Profit CAGR	-60%	-21%	-8%	-13%
PAT CAGR	0%	0%	0%	NAN%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	-6%	-2%	5%	4%
ROE Average	-5%	-1%	-1%	1%
ROCE Average	-1%	2%	1%	4%

GKB Ophthalmics Balance Sheet

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Shareholder's Funds	40	40	45	47	45	55	59	63	63	63	60
Minority's Interest	0	0	0	0	0	0	0	4	4	5	4
Borrowings	2	0	0	0	0	0	0	1	2	1	1
Other Non-Current Liabilities	1	1	2	2	2	5	5	5	6	6	7
Total Current Liabilities	30	33	23	37	36	37	41	38	39	41	46
Total Liabilities	73	75	69	86	83	97	106	111	114	116	118
Fixed Assets	14	12	13	18	18	26	26	24	23	19	18
Other Non-Current Assets	16	17	5	2	1	7	7	13	16	13	13
Total Current Assets	43	46	51	66	64	64	73	74	76	84	87
Total Assets	73	75	69	86	83	97	106	111	114	116	118

GKB Ophthalmics Cash Flow

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Opening Cash & Cash Equivalents	2	2	3	3	2	2	9	13	6	6	2
Cash Flow from Operating Activities	6	7	-11	-3	-3	4	3	7	5	-3	4
Cash Flow from Investing Activities	-2	-0	15	4	1	-10	-4	-17	-4	1	-2
Cash Flow from Financing Activities	-5	-6	-3	-1	1	13	4	3	-2	-2	-2
Net Cash Inflow / Outflow	-0	1	0	-1	0	7	4	-7	-0	-4	1
Closing Cash & Cash Equivalent	2	3	3	2	2	9	13	6	6	2	3

GKB Ophthalmics Ratios

#	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Earnings Per Share (Rs)	9.61	0.01	9.51	6.23	-2.34	-2.38	-3.65	-1.8	2.53	-0.33	-5.58
CEPS(Rs)	8.88	0.57	13.1	9.68	1.75	4.99	2.32	4.75	9.15	5.84	-0.17
DPS(Rs)	0	0	0	0	0	0	0	0	0	0	0
Book NAV/Share(Rs)	96.06	96.33	107.89	112.64	108.2	111.84	117.55	124.3	125.18	124.38	118.58
Core EBITDA Margin(%)	17.89	2.28	-3.82	2.39	1.72	2	3.65	3.37	6.83	4.88	0.66
EBIT Margin(%)	17.59	1.13	20.91	5.54	0.18	-0.37	-1.69	1.94	4.83	2.4	-0.99
Pre Tax Margin(%)	10.84	-5.65	17.33	3.85	-1.46	-2.97	-4.19	-1.63	2.74	0.18	-3.15
PAT Margin (%)	5.85	-3.57	8.67	3.38	-1.25	-2.14	-4.19	-1.32	2.74	0.15	-3.38
Cash Profit Margin (%)	8.72	0.64	11.93	5.26	0.93	4.05	2	4.21	6.5	3.9	-0.09
ROA(%)	3.39	-1.78	5.48	3.34	-1.15	-1.36	-2.41	-0.69	1.73	0.1	-2.55
ROE(%)	6.6	-3.3	9.32	5.65	-2.12	-2.52	-4.41	-1.23	3.09	0.18	-4.87
ROCE(%)	14.52	0.82	18.94	7.99	0.25	-0.34	-1.38	1.48	4.58	2.44	-1.2
Receivable days	170.23	194.91	142.03	99.83	122.19	162.83	151.07	142.44	100.29	114.24	116.09
Inventory Days	183.07	200.66	169.82	124.36	147.17	190.76	181.31	211.22	188.1	184.84	162.86
Payable days	173.66	265.65	192.73	126.99	165.17	231.94	221.09	234.2	200.8	190.02	173.79
PER(x)	3.03	4892.03	6.94	21.4	0	0	0	0	36.39	0	0
Price/Book(x)	0.3	0.52	0.61	1.18	1.07	0.83	0.37	0.66	0.73	0.87	0.74
Dividend Yield(%)	0	0	0	0	0	0	0	0	0	0	0
EV/Net Sales(x)	0.54	0.75	0.7	0.81	0.72	0.82	0.39	0.63	0.59	0.68	0.43
EV/Core EBITDA(x)	2.69	18.01	626.24	19.06	30.3	14.15	8.74	8.29	6.95	11.17	18.04
Net Sales Growth(%)	-3.15	-15.13	24.38	69.3	4.5	-26.17	2.4	-2.83	24.72	6.4	16.93
EBIT Growth(%)	346.84	-94.41	2193.92	-55.59	-96.77	-255.89	-362.64	211.85	210.17	-47.08	-148.14
PAT Growth(%)	327.18	-153.28	400.08	-34.53	-137.52	-25.86	-100.59	69.46	359.73	-94.02	-2664.14
EPS Growth(%)	669.13	-99.89	0	-34.53	-137.52	-1.8	-53.4	50.67	240.42	-113.14	-1578.92
Debt/Equity(x)	0.31	0.22	0.16	0.15	0.22	0.27	0.26	0.19	0.19	0.18	0.19
Current Ratio(x)	1.44	1.38	2.25	1.8	1.75	1.72	1.76	1.94	1.95	2.03	1.89
Quick Ratio(x)	0.8	0.75	1.32	0.96	0.87	0.97	1.02	1.01	0.98	1.09	1.03
Interest Cover(x)	2.6	0.17	5.84	3.28	0.11	-0.14	-0.67	0.54	2.32	1.08	-0.46
Total Debt/Mcap(x)	1.03	0.41	0.26	0.13	0.21	0.33	0.7	0.29	0.25	0.21	0.26

GKB Ophthalmics Shareholding Pattern

#	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoter	59.16	59.09	59.09	59.18	50.86	50.88	50.93	50.95	50.95	50.98
FII	1.98	1.98	1.79	1.79	1.79	1.79	1.79	1.79	1.79	1.79
DII	0	0	0	0	0	0	0	0	0	0
Public	38.86	38.93	39.12	39.03	47.35	47.33	47.28	47.27	47.27	47.23
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoter	0.3	0.3	0.3	0.3	0.26	0.26	0.26	0.26	0.26	0.26
FII	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
DII	0	0	0	0	0	0	0	0	0	0
Public	0.2	0.2	0.2	0.2	0.24	0.24	0.24	0.24	0.24	0.24
Others	0	0	0	0	0	0	0	0	0	0
Total	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5

Pros

Stock is trading at 0.8 times its book value
Debtor days have improved from 190.02 to 173.79days.
Company is almost debt free.

Cons

Company has a low return on equity of -1% over the last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.